Bio Essence Corp SEC filings BIOE
Bio Essence Corp has 87 filings in SEC EDGAR's recent list, going back to Nov 16, 2017. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (officer or director change, bylaw or fiscal year change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Oct 23, 2026 | Oct 15, 2026 |
| PRE 14C | Preliminary information statement | Oct 21, 2026 | Oct 21, 2026 |
| 4/A | Filing | Oct 14, 2026 | Oct 28, 2024 |
| 144 | Notice of proposed sale | Oct 13, 2026 | — |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K/A |
Amended current report
Material agreement
|
May 19, 2026 | Apr 24, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement
|
Apr 24, 2026 | Apr 24, 2026 |
| 10-K | Annual report | Mar 27, 2026 | Dec 31, 2025 |
| QUALIF | Filing | Jan 5, 2026 | — |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 1-A | Filing | Oct 17, 2025 | — |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| 10-K | Annual report | Mar 28, 2025 | Dec 31, 2024 |
| UPLOAD | Letter from the SEC | Dec 5, 2024 | — |
| 10-Q/A | Amended quarterly report | Nov 27, 2024 | Jun 30, 2024 |
| 10-Q/A | Amended quarterly report | Nov 27, 2024 | Mar 31, 2024 |
| 4 | Insider transaction | Nov 18, 2024 | Oct 28, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| UPLOAD | Letter from the SEC | Nov 8, 2024 | — |
| 10-Q/A | Amended quarterly report | Oct 30, 2024 | Jun 30, 2024 |
| 10-Q/A | Amended quarterly report | Oct 30, 2024 | Mar 31, 2024 |
| UPLOAD | Letter from the SEC | Oct 21, 2024 | — |
| 4/A | Filing | Oct 11, 2024 | Jun 6, 2023 |
| 4 | Insider transaction | Oct 10, 2024 | Jul 11, 2024 |
| 4/A | Filing | Oct 10, 2024 | Jul 2, 2024 |
| 144/A | Filing | Oct 9, 2024 | — |
| 144 | Notice of proposed sale | Oct 9, 2024 | — |
| 10-Q/A | Amended quarterly report | Oct 7, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Restatement
|
Oct 7, 2024 | Oct 7, 2024 |
| UPLOAD | Letter from the SEC | Sep 25, 2024 | — |
| 10-Q/A | Amended quarterly report | Aug 21, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | Aug 19, 2024 | Jun 30, 2024 |
| NT 10-Q | Notification of late filing | Aug 14, 2024 | Jun 30, 2024 |
| 8-K/A |
Amended current report
Auditor change
|
Aug 9, 2024 | Aug 5, 2024 |
| 8-K |
Current report
Auditor change
|
Aug 5, 2024 | Aug 5, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Jul 2, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Jun 21, 2024 | Jun 18, 2024 |
| 144 | Notice of proposed sale | Jun 3, 2024 | — |
| 4 | Insider transaction | Jun 3, 2024 | Jun 6, 2023 |
| 3 | Initial insider ownership | Jun 3, 2024 | Dec 8, 2017 |
| 10-Q | Quarterly report | May 17, 2024 | Mar 31, 2024 |
| NT 10-Q | Notification of late filing | May 15, 2024 | Mar 31, 2024 |
| 10-K | Annual report | Apr 15, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement
|
Apr 4, 2024 | Apr 4, 2024 |
| NT 10-K | Filing | Mar 27, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Dec 13, 2023 | Dec 13, 2023 |
| 10-Q | Quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 7, 2023 | Sep 7, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Other events
|
Jun 6, 2023 | Jun 6, 2023 |
| 10-Q | Quarterly report | May 12, 2023 | Mar 31, 2023 |
| 10-K | Annual report | Mar 30, 2023 | Dec 31, 2022 |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 15, 2022 | Jun 30, 2022 |
| 10-Q | Quarterly report | May 16, 2022 | Mar 31, 2022 |
| NT 10-Q | Notification of late filing | May 13, 2022 | Mar 31, 2022 |
| 10-K | Annual report | Mar 31, 2022 | Dec 31, 2021 |
| 10-Q | Quarterly report | Nov 12, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 12, 2021 | Jun 30, 2021 |
| 10-Q | Quarterly report | May 11, 2021 | Mar 31, 2021 |
| 10-K | Annual report | Apr 14, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Auditor change
|
Apr 13, 2021 | Apr 13, 2021 |
| NT 10-K | Filing | Mar 25, 2021 | Dec 31, 2020 |
| 8-A12G | Form 8-a12g | Mar 25, 2021 | — |
| EFFECT | Filing | Dec 30, 2020 | — |
| CORRESP | Letter to the SEC | Dec 30, 2020 | — |
| S-1/A | Amended registration statement | Dec 23, 2020 | — |
| CORRESP | Letter to the SEC | Dec 22, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2020 | — |
| S-1/A | Amended registration statement | Nov 25, 2020 | — |
| CORRESP | Letter to the SEC | Mar 27, 2020 | — |
| S-1/A | Amended registration statement | Mar 27, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 27, 2020 | — |
| S-1/A | Amended registration statement | Mar 12, 2020 | — |
| UPLOAD | Letter from the SEC | Feb 25, 2020 | — |
| S-1/A | Amended registration statement | Feb 10, 2020 | — |
| CORRESP | Letter to the SEC | Feb 7, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 26, 2019 | — |
| DEL AM | Filing | Nov 5, 2019 | — |
| S-1/A | Amended registration statement | Oct 28, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2019 | — |
| S-1 | Registration statement | Jul 26, 2019 | — |
| D | Filing | Jul 24, 2019 | — |
| D/A | Filing | Jan 3, 2018 | — |
| D | Filing | Nov 16, 2017 | — |
Showing 87 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIOE (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Irvine, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1723059
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.